Kiora Pharmaceuticals Inc
NASDAQ:KPRX 4:00:00 PM EDT
| Market Cap (Intraday) | 9.13M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $2.98 |
| 50-Day MA | $3.09 |
| 200-Day MA | $3.31 |
Kiora Pharmaceuticals Inc Stock, NASDAQ:KPRX
332 Encinitas Boulevard, Suite 102, Encinitas, California 92024
United States of America
Phone: +1.858.224.9600
Number of Employees: 12
Description
Kiora Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes KIO-301, which is designed to restore vision in patients with inherited and age-related degenerative retinal disease, KIO-101 for patients with Ocular Presentation of Rheumatoid Arthritis, KIO-201 for patients undergoing PRK surgery for corneal wound repair after refractive surgery, and KIO-102. The company was founded in 1998 and is headquartered in Encinitas, CA.